الرئيسية
/
قاعدة بيانات الهيئة على الإنترنت
/
قاعدة بيانات بقايا الأدوية البيطرية في الأغذية
/
الفئات الوظيفية
/
تفاصيل الفئات الوظيفية للأدوية البيطرية
Adrenoceptor agonist
تم العثور على 1 من الأدوية البيطرية التي تحتوي على حدود الحد الأقصى من البقايا (MRLs) وتلبي المعايير التالية:
Adrenoceptor agonist
Clenbuterol (14)
الحدود القصوى للبقايا لـ Clenbuterol (14)
| الأنواع | الأنسجة | MRL | الملاحظات | السنة |
|---|---|---|---|---|
| Cattle | Muscle | 0.2 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Horse | Liver | 0.6 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Cattle | Liver | 0.6 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Horse | Muscle | 0.2 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Horse | Kidney | 0.6 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Horse | Fat | 0.2 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Cattle | Fat | 0.2 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Cattle | Kidney | 0.6 µg/kg |
Due to the potential abuse of this drug, the MRLs are recommended only when associated with a nationally approved therapeutic use, such as tocolysis or as an adjunt therapy in respiratory diseases.
|
2003 |
| Cattle | Milk | 0.05 µg/l | 2003 |